Table 2.
Participant Baseline Characteristics by Listing Status and Treatment Strategy.
| Not Listed | Listed | |||||
|---|---|---|---|---|---|---|
| CON | INV | P-value* | CON | INV | P-value* | |
| (n=289) | (n=294) | (n=100) | (n=94) | |||
| Age at randomization, years | 0.040 | 0.907 | ||||
| N | 289 | 294 | 100 | 94 | ||
| Median (Q1, Q3) | 66 (58, 73) | 64 (56, 71) | 61 (53, 65) | 59 (54, 64) | ||
| Female | 0.748 | 0.802 | ||||
| Female | 98/289 (34%) | 95/294 (32%) | 24/100 (24%) | 25/94 (27%) | ||
| Race | 0.433 | 0.922 | ||||
| American Indian or Alaskan Native | 2/281 (1%) | 0/286 (0%) | 1/93 (1%) | 2/87 (2%) | ||
| Asian | 87/281 (31%) | 77/286 (27%) | 13/93 (14%) | 14/87 (16%) | ||
| Native Hawaiian or Other Pacific Islander | 2/281 (1%) | 1/286 (0%) | 2/93 (2%) | 1/87 (1%) | ||
| Black or African American | 20/281 (7%) | 25/286 (9%) | 10/93 (11%) | 8/87 (9%) | ||
| White | 170/281 (60%) | 182/286 (64%) | 67/93 (72%) | 62/87 (71%) | ||
| Multiple Races Reported | 0/281 (0%) | 1/286 (0%) | 0/93 (0%) | 0/87 (0%) | ||
| Degree of ischemia on stress test | 0.540 | 0.850 | ||||
| Moderate | 165/286 (58%) | 175/289 (61%) | 69/100 (69%) | 67/94 (71%) | ||
| Severe | 121/286 (42%) | 114/289 (39%) | 31/100 (31%) | 27/94 (29%) | ||
| Hypertension | 0.184 | 0.665 | ||||
| 270/287 (94%) | 267/294 (91%) | 92/100 (92%) | 82/92 (89%) | |||
| Diabetes | 0.989 | 0.341 | ||||
| 163/289 (56%) | 167/294 (57%) | 55/100 (55%) | 59/94 (63%) | |||
| Smoke status | 0.616 | 0.951 | ||||
| Never smoked | 139/289 (48%) | 141/294 (48%) | 46/100 (46%) | 45/94 (48%) | ||
| Former smoker | 118/289 (41%) | 113/294 (38%) | 48/100 (48%) | 43/94 (46%) | ||
| Current Smoker | 32/289 (11%) | 40/294 (14%) | 6/100 (6%) | 6/94 (6%) | ||
| Previous myocardial infarction | 0.528 | 0.815 | ||||
| 57/289 (20%) | 51/294 (17%) | 14/100 (14%) | 11/93 (12%) | |||
| Previous heart failure | 0.599 | 1.000 | ||||
| 56/289 (19%) | 51/294 (17%) | 14/100 (14%) | 14/94 (15%) | |||
| Previous stroke | 0.350 | 0.476 | ||||
| 23/289 (8%) | 31/294 (11%) | 9/100 (9%) | 5/94 (5%) | |||
| History of cerebrovascular disease or PAD† | 0.291 | 0.599 | ||||
| 50/289 (17%) | 62/294 (21%) | 13/100 (13%) | 9/94 (10%) | |||
| Previous PCI‡ | 0.910 | 1.000 | ||||
| 53/289 (18%) | 56/294 (19%) | 19/100 (19%) | 18/94 (19%) | |||
| Previous CABG§ | 1.000 | 1.000 | ||||
| 8/289 (3%) | 9/294 (3%) | 6/100 (6%) | 5/94 (5%) | |||
| Ejection fraction (%) | 0.484 | 0.184 | ||||
| N | 221 | 242 | 79 | 77 | ||
| Median (Q1, Q3) | 58 (50, 64) | 57 (50, 63) | 60 (52, 65) | 58 (50, 61) | ||
| On dialysis | 0.549 | 0.180 | ||||
| 130/289 (45%) | 124/294 (42%) | 87/100 (87%) | 74/94 (79%) | |||
| Duration of dialysis (years) | 0.333 | 0.414 | ||||
| N | 114 | 110 | 78 | 67 | ||
| Median (Q1, Q3) | 2 (1, 5) | 3 (1, 6) | 2 (1, 3) | 2 (1, 5) | ||
| Dialysis type | 0.676 | 0.551 | ||||
| Peritoneal dialysis | 13/124 | 16/123 | 15/86 | 16/71 | ||
| (10%) | (13%) | (17%) | (23%) | |||
| eGFRǁ among those not receiving dialysis (ml/min/1.73m2) | 0.848 | 0.567 | ||||
| N | 159 | 170 | 13 | 20 | ||
| Median (Q1, Q3) | 23 (18, 27) | 23 (17, 27) | 16 (13, 19) | 16 (15, 20) | ||
| #SAQ Summary score | 0.611 | 0.961 | ||||
| N | 269 | 267 | 97 | 91 | ||
| Median (Q1, Q3) | 75 (60, 88) | 72 (54, 92) | 90 (75, 100) | 92 (78, 98) | ||
| #SAQ Angina Frequency score | 0.424 | 0.202 | ||||
| N | 269 | 267 | 97 | 91 | ||
| Median (Q1, Q3) | 90 (80, 100) | 90 (70, 100) | 100 (90, 100) | 100 (100, 100) | ||
| #SAQ Physical Limitation score | 0.739 | 0.360 | ||||
| N | 200 | 216 | 83 | 76 | ||
| Median (Q1, Q3) | 75 (56, 92) | 75 (50, 100) | 92 (67, 100) | 100 (75, 100) | ||
| #SAQ Quality of Life score | 0.685 | 0.738 | ||||
| N | 268 | 267 | 97 | 91 | ||
| Median (Q1, Q3) | 63 (38, 88) | 63 (38, 88) | 88 (50, 100) | 88 (63, 100) | ||
| Canadian Cardiovascular Society angina class | 0.964 | 0.240 | ||||
| None | 82/289 (28%) | 89/294 (30%) | 56/99 (57%) | 65/94 (69%) | ||
| I | 60/289 (21%) | 58/294 (20%) | 23/99 (23%) | 14/94 (15%) | ||
| II | 132/289 (46%) | 132/294 (45%) | 19/99 (19%) | 15/94 (16%) | ||
| III | 15/289 (5%) | 15/294 (5%) | 1/99 (1%) | 0/94 (0%) | ||
| New York Heart Association class | 0.579 | 0.338 | ||||
| I | 48/168 (29%) | 51/169 (30%) | 23/43 (53%) | 14/35 (40%) | ||
| II | 119/168 (71%) | 118/169 (70%) | 20/43 (47%) | 21/35 (60%) | ||
| III | 1/168 (1%) | 0/169 (0%) | 0/43 (0%) | 0/35 (0%) | ||
| Type of stress testing | 0.377 | 0.755 | ||||
| Nuclear | 185/288 (64%) | 173/293 (59%) | 60/100 (60%) | 61/94 (65%) | ||
| ECHO** | 44/288 (15%) | 56/293 (19%) | 29/100 (29%) | 23/94 (24%) | ||
| CMR†† | 1/288 (0%) | 0/293 (0%) | 0/100 (0%) | 0/94 (0%) | ||
| ETT‡‡ | 58/288 (20%) | 64/293 (22%) | 11/100 (11%) | 10/94 (11%) | ||
*
P-values were obtained using the Wilcoxon Rank Sum test for continuous variables. For categorical variables, Pearson’s chi-squared test was used. Initial Invasive (INV) and Initial Conservative (CON) strategy arms.
†
PAD: peripheral arterial disease
‡
PCI: percutaneous coronary intervention
§
CABG: coronary artery bypass graft
ǁ
eGFR: estimated glomerular filtration rate
#
SAQ: Seattle Angina Questionnaire
**
ECHO: echocardiography
††
CMR: Cardiac Magnetic Resonance Imaging
‡‡
ETT: exercise treadmill test;